Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 697 across all filing types
Latest filing 2026-04-13 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a news release describing preclinical study results and forward-looking statements, rather than a financial report, management discussion, earnings release, or regulatory filing like an annual or interim report. It does not announce voting results, dividends, financing, or corporate governance changes. It is not a presentation deck or transcript. It is a corporate press release with scientific data aimed at investors and the public, which falls into the fallback category for miscellaneous regulatory announcements and press releases. Therefore, it should be classified as a Regulatory Filings (RNS) document.
2026-04-13 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing preclinical study results for Theralase® Technologies, describing animal trial outcomes and future clinical plans. It does not present financial results, management changes, dividends, securities transactions, or an actual regulatory filing form like a 10-K or interim report. It is not an investor presentation or proxy solicitation; rather, it is general company news distributed via Newsfile and SEDAR. Therefore it falls under the fallback category of Regulatory Filings (RNS) for miscellaneous announcements that do not fit other specific filing types.
2026-04-13 English
News release - English.pdf
Capital/Financing Update Classification · 94% confidence The document is a press release announcing the closing of a non‐brokered private placement and a revolving line of credit. It details the fundraising amounts, unit issuance, warrant terms, use of proceeds, related party transactions, and exchange approval. This is not an earnings release, regulatory filing, or report publication announcement, but clearly an update on the company’s financing activity. Therefore, it should be classified as a Capital/Financing Update (CAP).
2026-04-10 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a corporate press release announcing the successful closing of a non-brokered private placement financing and a new revolving line of credit, including details on units issued, warrants, related party subscriptions, and use of proceeds. This is clearly an update on company fundraising and capital structure. Therefore, it falls under Capital/Financing Update (CAP).
2026-04-10 English
Material change report - English.pdf
Regulatory Filings
2026-03-25 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2026-03-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.